NCT00203879View on ClinicalTrials.gov

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2007

Conditions
Metastatic Melanoma
Interventions
DRUG

MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)

draft

DRUG

MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2

MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00203879 - Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma | Biotech Hunter | Biotech Hunter